
In the early 2000s, a new cancer drug was on the horizon. Called cetuximab, it was an immunotherapy created for metastatic colorectal cancer. Pharmaceutical companies ImClone Systems and Bristol Meyers Squibb ran clinical trials across the US for the drug in 2004. Soon enough, it became apparent something was very wrong.